Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
ASH 2020 | Updates at ASH 2020 on bispecific antibodies in MM
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses the progress being made in the field of bispecific antibodies in multiple myeloma.
Idecabtagene vicleucel (ide-cel) updated findings in heavily pretreated myeloma ...
In an interview with Targeted Oncology, Yi Lin, MD, PhD discussed the updated findings from the CRB-401 study of idecabtagene vicleucel as treatment of patients with relapsed/refractory multiple myeloma.
Latest updates in myeloma: key takeaways from ASH 2020
Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses recent advances in multiple myeloma research that were presented at ASH 2020.
Impact of age on ide-cel efficacy in the KarMMa trial
Jesus Berdeja, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the updated results from KarMMa (NCT03361748), a study aiming to evaluate the efficacy and safety of idecabtagene vicleucel (ide-cel, bb2121) in relapsed/refractory (R/R) multiple myeloma.
Patient resource | It’s all about the antibodies! How mAbs work in Multiple Myel...
"To understand how a monoclonal antibody works first you need to know what an antigen is. An antigen is a molecule that is able to generate antibodies in our immune system." - Read this review by Cindy Chmielewski on the mechanism of action (how they work) of each type of antibody.
Do mAbs and paraprotein affect COVID-19 Serological Testing in Patients with Mul...
SARS-CoV-2 (COVID-19) serology tests do not appear to interfere or cause cross-reactivity with therapeutic monoclonal antibody (t-mAb) treatments for hematologic malignancies (HM) such as multiple myeloma (MM), according to a study published in Diagnostics.
ASH 2020 | CRB-401: ide-cel for R/R multiple myeloma
In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the Phase I CRB-401 (NCT02658929) study, a non-randomized, open-label, multi-site study of idecabtagene vicleucel in adults with relapsed/refractory (R/R) multiple myeloma.
ASH 2020 | CARTITUDE-1: latest data & CRS in myeloma treated with cilta-cel
In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on CARTITUDE-1 (NCT03548207), a study which investigated the use of cilta-cel in relapsed/refractory (R/R) multiple myeloma and highlights cytokine release syndrome (CRS) in those treated.
Highlights in the myeloma field to come at ASH 2020
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what highlights there are to look forward to in the multiple myeloma field at ASH 2020
iwCAR-T meeting 2020: featured sessions
During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.